CG Oncology (CGON) Accumulated Depreciation & Amortization (2024 - 2026)

CG Oncology (CGON) has 3 years of Accumulated Depreciation & Amortization data on file, last reported at $2.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Depreciation & Amortization changed N/A year-over-year to $2.3 million; the trailing twelve-month figure through Mar 2026 stood at $2.3 million (changed N/A YoY), and the FY2025 full-year result was $1.5 million, up 1594.25% from the prior year.
• Accumulated Depreciation & Amortization for Q1 2026 stood at $2.3 million, up from $1.5 million in the prior quarter.
• Across five years, Accumulated Depreciation & Amortization topped out at $2.3 million in Q1 2026 and bottomed at $87000.0 in Q4 2024.
• The 3-year median for Accumulated Depreciation & Amortization is $1.0 million (2025), against an average of $1.1 million.
• Peak annual rise in Accumulated Depreciation & Amortization reached 1594.25% in 2025, while the deepest fall reached 1594.25% in 2025.
• A 3-year view of Accumulated Depreciation & Amortization shows it stood at $87000.0 in 2024, then jumped by 1594.25% to $1.5 million in 2025, then surged by 55.63% to $2.3 million in 2026.
• The last three Accumulated Depreciation & Amortization figures came in at $2.3 million (Q1 2026), $1.5 million (Q4 2025), and $623000.0 (Q3 2025), per Business Quant data.

Peer Comparison